Lupus (SLE) trials in South Korea

In South Korea 17 Also abroad 354

17 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Seoul
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Taking people
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Where
Gwangju, Seoul
Age
12 years to 100 years
People
550 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00
Phase 3Taking people
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Where
Seoul, Suwon
Age
18 years to 100 years
People
348 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06711887 · EU 2024-515280-60-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Where
Ansan-si, Incheon, Seongnam-si, Seoul
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00
Phase 3Taking people
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
Where
Seongnam-si, Seoul
Age
18 years to 75 years
People
202 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00
Phase 3Taking people
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Where
Busan, Gwangju, Gyeonggi-do, Seoul, Suwon
Age
18 years to 75 years
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Where
Busan, Incheon, Seoul, Suwon
Age
16 years and over
People
450 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00
Phase 1Taking people
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Where
Anyang-si, Seoul
Age
18 years to 60 years
People
90 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06975787 · EU 2024-518288-37-00
Phase 3Enrolling by invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
Where
Incheon, Seoul
Age
16 years and over
People
760 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00
Phase 3Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Where
Seoul, Suwon
Age
18 years and over
People
864 worldwide
Run by
Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00
Phase 1Taking people
CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus
Where
Seoul
Age
Up to 25 years
People
8
Run by
Seoul National University Hospital
See details and how to joinNCT07855302
Phase 1Enrolling by invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
Where
Seoul
Age
18 years and over
People
52 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT07038447
Phase 3Enrolling by invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Where
Seoul
Age
18 years to 75 years
People
680 worldwide
Run by
Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00
Phase 2Taking people
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Where
Daegu, Gwangju
Age
18 years to 75 years
People
256 worldwide
Run by
Eisai Co., Ltd.
See details and how to joinNCT07515014
No phaseTaking people
Reduced Vaccine Response to HZ/su in SLE
Where
Seoul
Age
50 years and over
People
80
Run by
Seoul National University Hospital
See details and how to joinNCT07636044
No phaseTaking people
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Where
Seoul
Age
18 years and over
People
5,000 worldwide
Run by
Monash University
See details and how to joinNCT03138941
No phaseTaking people
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Where
Chuncheon, Daegu, Seoul
People
3,000
Run by
Seoul National University Hospital
See details and how to joinNCT03929887